Picture loading failed.

Anti-CD276 therapeutic antibody (Pre-made Enoblituzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1�� monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-184-1mg 1mg 3090
GMP-Bios-ab-184-10mg 10mg 21890
GMP-Bios-ab-184-100mg 100mg 148000
GMP-Bios-ab-184-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD276 therapeutic antibody (Pre-made Enoblituzumab biosimilar,Whole mAb)
INN Name Enoblituzumab
TargetCD276
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2017
CompaniesMacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions Approvedna
Conditions ActiveProstate cancer;Solid tumours;Head and neck cancer
Conditions DiscontinuedMalignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer
Development Techna